体部立体定向放射治疗联合免疫检查点抑制剂在非小细胞肺癌中的应用

doi:10.3760/cma.j.cn371439-20210126-00019

摘要/Abstract

摘要：

针对非小细胞肺癌(NSCLC),目前的主要治疗手段是手术、化疗、放疗、靶向治疗、免疫治疗等多种疗法的结合。立体定向放射治疗(SBRT)的应用越来越广泛,基于SBRT的免疫调节效应,SBRT联合免疫检查点抑制剂(ICI)可应用于各期别NSCLC。SBRT联合ICI治疗模式需不断探索以发挥最佳的放射免疫协同作用。

关键词: 癌,非小细胞肺, 免疫检查点抑制剂, 立体定向放射治疗

Abstract:

The major treatments of non-small cell cancer (NSCLC) contain surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy and the combinations of them. Among them, stereotactic body radiation therapy (SBRT) is applied more and more extensively. Based on the immunoregulatory effects of SBRT, the combination with immune checkpoint inhibitors (ICIs) is used in all stages of NSCLC. This kind of treatment mode needs to be continuously explored to maximize the radio-immunity synergistic effect.

Key words: Carcinoma,non-small-cell lung, Immune checkpoint inhibitors, Stereotactic body radiation therapy

李坪, 孙晓南. 体部立体定向放射治疗联合免疫检查点抑制剂在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 116-120.

Li Ping, Sun Xiaonan. Application of the combination of stereotactic body radiation therapy and immune checkpoint inhibitors in non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 116-120.

参考文献 39

[1]	Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6): 630-637. DOI: 10.1016/S1470-2045(15)70168-3. doi: 10.1016/S1470-2045(15)70168-3 pmid: 25981812
[2]	白馨雅, 张金梦, 孙洋, 等. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8): 500-504. DOI: 10.3760/cma.j.issn.1673-422X.2019.08.012. doi: 10.3760/cma.j.issn.1673-422X.2019.08.012
[3]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemothe-rapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. J Clin Oncol, 2019, 37(7): 537-546. DOI: 10.1200/JCO.18.00149. doi: 10.1200/JCO.18.00149
[4]	Qiao M, Jiang T, Ren S, et al. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: where do we stand?[J]. Clin Lung Cancer, 2018, 19(1): 1-11. DOI: 10.1016/j.cllc.2017.06.005. doi: 10.1016/j.cllc.2017.06.005
[5]	Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy[J]. JAMA Oncol, 2015, 1(9): 1325-1332. DOI: 10.1001/jamaoncol.2015.2756. doi: 10.1001/jamaoncol.2015.2756 pmid: 26270858
[6]	Lin AJ, Roach M, Bradley J, et al. Combining stereotactic body radiation therapy with immunotherapy: current data and future directions[J]. Transl Lung Cancer Res, 2019, 8(1): 107-115. DOI: 10.21037/tlcr.2018.08.16. doi: 10.21037/tlcr.2018.08.16
[7]	Lippitz BE, Harris RA. A translational concept of immuno-radiobiology[J]. Radiother Oncol, 2019, 140:116-124. DOI: 10.1016/j.radonc.2019.06.001. doi: S0167-8140(19)32937-8 pmid: 31271996
[8]	Hwang WL, Pike LRG, Royce TJ, et al. Safety of combining radiotherapy with immune-checkpoint inhibition[J]. Nat Rev Clin Oncol, 2018, 15(8): 477-494. DOI: 10.1038/s41571-018-0046-7. doi: 10.1038/s41571-018-0046-7
[9]	Onderdonk BE, Chmura SJ. The yin and yang of cytoreductive SBRT in oligometastases and beyond[J]. Front Oncol, 2019, 9:706. DOI: 10.3389/fonc.2019.00706. doi: 10.3389/fonc.2019.00706 pmid: 31428580
[10]	Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322. DOI: 10.1038/nrc.2018.6. doi: 10.1038/nrc.2018.6
[11]	Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination?[J]. Ther Adv Med Oncol, 2018, 10: 1758835918768240. DOI: 10.1177/1758835918768240. doi: 10.1177/1758835918768240
[12]	Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial[J]. Lancet Oncol, 2019, 20(4): 494-503. DOI: 10.1016/S1470-2045(18)30896-9. doi: 10.1016/S1470-2045(18)30896-9
[13]	Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?[J]. Nat Rev Clin Oncol, 2016, 13(8): 516-524. DOI: 10.1038/nrclinonc.2016.30. doi: 10.1038/nrclinonc.2016.30 pmid: 26951040
[14]	Chang JY, Lin SH, Yao LY, et al. Ⅰ-SABR phase Ⅱ randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: interim analysis adverse effects[J]. J Clin Oncol, 2020, 38(15_suppl): 9035. DOI: 10.1200/JCO.2020.38.15_suppl.9035. doi: 10.1200/JCO.2020.38.15_suppl.9035
[15]	Troost E, Robinson C, Hu C, et al. PACIFIC-4/RTOG 3515: phase Ⅲ study with durvalumab after SBRT in inoperable,lymph node-negative stage Ⅰ/Ⅱ NSCLC[J]. Strahlenther Onkol, 2020, 196(SUPPL 1): S86.
[16]	Jabbour SK, Houghton B, Robinson AG, et al. Phase 3, Randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with inoperable stage Ⅰ/ⅡA non-small-cell lung cancer (NSCLC): KEYNOTE-867[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3): e135-e136. DOI: 10.1016/j.ijrobp.2020.07.1289. doi: 10.1016/j.ijrobp.2020.07.1289
[17]	Altorki N, Borczuk A, Saxena A, et al. P2.04-92 neoadjuvant durvalumab with or without sub-ablative stereotactic radiotherapy (SBRT) in patients with resectable NSCLC (NCT02904954)[J]. J Thorac Oncol, 2019, 14(10): S746. DOI: 10.1016/j.jtho.2019.08.1597. doi: 10.1016/j.jtho.2019.08.1597
[18]	Hendriks LEL, Dooms C, Berghmans T, et al. Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion[J]. Eur J Cancer, 2019, 123:28-35. DOI: 10.1016/j.ejca.2019.09.013. doi: S0959-8049(19)30735-X pmid: 31655358
[19]	Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): e18-e28. DOI: 10.1016/S1470-2045(19)30718-1. doi: 10.1016/S1470-2045(19)30718-1
[20]	Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial[J]. JAMA Oncol, 2019, 5(9): 1283-1290. DOI: 10.1001/jamaoncol.2019.1449. doi: 10.1001/jamaoncol.2019.1449
[21]	Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282. DOI: 10.1001/jamaoncol.2019.1478. doi: 10.1001/jamaoncol.2019.1478
[22]	Chen D, Menon H, Verma V, et al. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials[J]. J Immunother Cancer, 2020, 8(1): e000492. DOI: 10.1136/jitc-2019-000492. doi: 10.1136/jitc-2019-000492
[23]	Campbell AM, Cai WL, Burkhardt D, et al. Final results of a phase Ⅱ prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC)[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1): S36-S37. DOI: 10.1016/j.ijrobp.2019.06.453. doi: 10.1016/j.ijrobp.2019.06.453
[24]	Rekers NH, Olivo Pimentel V, Yaromina A, et al. The immunocytokine L19-IL2: an interplay between radiotherapy and long-lasting systemic anti-tumour immune responses[J]. Oncoimmunology, 2018, 7(4): e1414119. DOI: 10.1080/2162402X.2017.1414119. doi: 10.1080/2162402X.2017.1414119
[25]	Lieverse RIY, Van Limbergen EJ, Oberije CJG, et al. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage Ⅳ NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase Ⅱ trial[J]. BMC Cancer, 2020, 20(1): 557. DOI: 10.1186/s12885-020-07055-1. doi: 10.1186/s12885-020-07055-1 pmid: 32539805
[26]	Stephans KL, Woody NM, Reddy CA, et al. Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage Ⅰ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 100(2): 462-469. DOI: 10.1016/j.ijrobp.2017.10.037. doi: 10.1016/j.ijrobp.2017.10.037
[27]	Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 103(5): 1077-1084. DOI: 10.1016/j.ijrobp.2018.11.051. doi: 10.1016/j.ijrobp.2018.11.051
[28]	Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy[J]. Clin Cancer Res, 2018, 24(20): 5058-5071. DOI: 10.1158/1078-0432.CCR-17-3427. doi: 10.1158/1078-0432.CCR-17-3427 pmid: 29898992
[29]	Käsmann L, Eze C, Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 225-226. DOI: 10.1016/j.ijrobp.2020.04.002. doi: 10.1016/j.ijrobp.2020.04.002
[30]	Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618. DOI: 10.1200/JCO.2017.76.2229. doi: 10.1200/JCO.2017.76.2229
[31]	Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase Ⅱ randomized trial[J]. J Clin Oncol, 2020, 38(25): 2830-2838. DOI: 10.1200/JCO.20.00818. doi: 10.1200/JCO.20.00818
[32]	Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2): 123-135. DOI: 10.1038/s41571-018-0119-7. doi: 10.1038/s41571-018-0119-7 pmid: 30401936
[33]	Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. doi: 10.1056/NEJMoa1809697
[34]	Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One, 2016, 11(6): e0157164. DOI: 10.1371/journal.pone.0157164. doi: 10.1371/journal.pone.0157164
[35]	Haanen JB, Thienen Hv, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations[J]. Semin Oncol, 2015, 42(3): 423-428. DOI: 10.1053/j.seminoncol.2015.02.011. doi: 10.1053/j.seminoncol.2015.02.011 pmid: 25965360
[36]	Tian SB, Switchenko JM, Buchwald ZS, et al. Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 304-313. DOI: 10.1016/j.ijrobp.2019.12.030. doi: 10.1016/j.ijrobp.2019.12.030
[37]	Chicas-Sett R, Zafra-Martin J, Morales-Orue I, et al. Immunoradiotherapy as an effective therapeutic strategy in lung cancer: from palliative care to curative intent[J]. Cancers (Basel), 2020, 12(8): 2178. DOI: 10.3390/cancers12082178. doi: 10.3390/cancers12082178
[38]	Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an Independent predictor of response to immunotherapy in diverse cancers[J]. Mol Cancer Ther, 2017, 16(11): 2598-2608. DOI: 10.1158/1535-7163.MCT-17-0386. doi: 10.1158/1535-7163.MCT-17-0386 pmid: 28835386
[39]	Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity[J]. Cancer Res, 2015, 75(11): 2232-2242. DOI: 10.1158/0008-5472.CAN-14-3511. doi: 10.1158/0008-5472.CAN-14-3511 pmid: 25858148